Please login to the form below

Not currently logged in
Email:
Password:

Merck plans expanded filing for Emend this year

Nausea and vomiting therapy more effective than placebo in 1000-patient trial

Merck and Co - US headquartersMerck & Co's nausea and vomiting therapy Emend is effective in preventing chemotherapy-induced nausea and vomiting (CINV) even when given as a single dose, says a new study.

The 1,000-patient trial revealed that a 150mg injection of neurokinin 1 antagonist Emend (fosaprepitant dimeglumine) was more effective than placebo – both given in combination with oral anti-vomiting drugs ondansetron and dexamethasone – in patients taking moderately-emetogenic chemotherapy (MEC). 

The single-dose regimen is already approved for use in highly-emetogenic chemotherapy (HEC), but Merck says it will now file the results with regulators later this year to broaden Emend's use to include chemotherapy regimens less prone to causing sickness.

All told, 79% of Emend treatment had a complete response – defined as no vomiting or use of additional medications to control nausea in the two to five-day period after chemotherapy - compared to 68.5% of the placebo group.

“Nausea and vomiting remain a significant burden for patients receiving chemotherapy and we look forward to submitting these data for Emend for injection to the FDA,” said Stuart Green, vice president of clinical research at Merck Research Laboratories.

Emend has been a solid product for Merck & Co, with sales last year rising 9% to reach $553m, but is approaching the end of its patent life. The US patent for the oral formulation expires this year, but the injectable remains protected until 2019, according to Merck.

The injectable formulation has been challenged however, with Merck filing a lawsuit in 2012 seeking to block a generic developed by Sandoz, and subsequent suits filed against Accord Healthcare/Intas and Fresenius. 

An automatic 30-month stay on launch of the Sandoz generic comes to an end next month, although the litigation is still moving through the court process. The 30-month stays on the launch of the other generics come to an end next year. 

In the meantime Merck is also facing a challenge on its injectable patent from Apotex, which filed a petition with the US Patent and Trademark Office (USPTO) last December.

Generics aside, competition is building in the CINV sector. Last October the FDA approved Eisai's combination Akynzeo (netupitant and palonosterol), while Tesaro's oral and injectable NK1 antagonist rolapitant was submitted for approval last September.

Article by
Phil Taylor

30th June 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Covid-19 drives change in long-term conditions management
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home...
The importance of health literacy in patient recruitment materials
Have you ever read something that instantly made you want to read on? Or have you begun to read something, and eventually given up because it didn’t resonate with you?...
Secondary effects of COVID-19 on the healthcare system and patients
We are getting to the point where we need to start considering the long-term effects on the healthcare system when making decisions....

Infographics